March
16, 2022 mDouglas Holtz-Eakin
United
States Senate, Committee on Finance
*
The views expressed here are my own and not those of the American Action Forum.
I thank Christopher Holt, Tara O’Neill Hayes, and Margaret Barnhorst for their
assistance.
Introduction
Chairman
Wyden, Ranking Member Crapo, and members of the committee, thank you for the
opportunity to discuss prescription drug prices and proposals for lowering them
included in the House-passed Build Back Better Act (BBBA). In this testimony, I
hope to make five main points:
·
The BBBA would establish
an explicit government price-setting regime for pharmaceuticals, reaching into
all corners of the U.S. health sector, both public and private;
·
The BBBA proposals would
harm consumers and negatively impact health equity through reduced innovation
and higher launch prices for drugs and therapies;
·
The BBBA proposals would
harm and endanger the economic activity generated by the biopharmaceutical
industry in the United States;
·
There are better ways to
lower drug prices than those put forward in the BBBA; and
·
Reducing drug prices
should in no way be framed as addressing the consumer price inflation problem
in the United States.
Let
me discuss each of these in greater detail.
Background
Annual
health care spending in the United States increased 9.7 percent in
2020, totaling $4.1 trillion. While the COVID-19 pandemic has played a role in
recent increases, health care spending and costs have both been growing rapidly
for years. In 2020, 19.7 percent of the U.S. economy was devoted to health care
spending.[1] Prescription
drugs, however, make up a relatively small percentage of total health care
spending. According to the Centers for Medicare and Medicaid Services (CMS),
retail prescription drug spending made up just 8.4 percent of all
U.S. health care spending in 2020.[2] While
those figures do not account for therapies administered by providers in
hospitals, nursing homes, or similar settings, the consulting firm
Altarum estimates that non-retail prescription drug spending accounts
for 4.5 percent of overall health care expenditures annually.[3]
Though
total spending on prescription therapies is not a large share of overall health
spending, patients are more likely to bear the cost of medication directly due
to the high coinsurance and deductibles increasingly common to drug coverage.
As a result, it is widely accepted that drug prices are higher than they
reasonably should be, and many argue that drugmaker profits are larger than
appropriate. This thinking fails to acknowledge the high risk associated with
pharmaceutical development, however. On average it takes more than a decade to
bring a drug to market, and most therapies never get there. Between 2011 and
2020, only 7.9 percent of compounds that started Phase 1 clinical trials made
it to market.[4] Calculating
how much was spent on a particular drug’s development and then calculating a
“fair” percentage markup for profit fails to account for investment in
unsuccessful research efforts, or the inherent risk investors take when they
provide research and development (R&D) capital to innovators. A reasonable
return on investment (ROI) will look different if the risk of failure is
higher, and investors expect a higher ROI in exchange for the risks related to
pharmaceutical development relative to other investment options. In the absence
of sufficient ROI, venture capital for pharmaceutical innovation will become
increasingly scarce.
Nonetheless, there is bipartisan concern over
the increasing cost of many biopharmaceutical therapies, but policymakers have
differed on the best approaches to addressing prescription drug prices. While
the Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3) has been debated
extensively, [5] far
less attention has been given to the drug policies that were included in the
House-passed Build Back Better Act (BBBA). The BBBA’s drug price
provisions are, however, no less egregious and pose no less risk to consumers
and the U.S. biopharmaceutical sector than those of H.R. 3. The BBBA’s drug
policies would dramatically curtail future innovation and would imperil the
economic benefits the United States derives from the biopharmaceutical sector.
BBBA’s Overall Impact on Innovation
At
the most basic level, any policies that reduce pharmaceutical industry revenue
will have downward pressure on future innovation. In a recent paper from the
University of Chicago, Tomas Philipson and Troy Durie estimate that a 1 percent
reduction in pharmaceutical industry revenue leads on average to a 1.54 percent
drop in R&D spending.[6] This
does not mean that any policy that reduces industry revenue is inherently
misguided, but policymakers need to be cognizant about the potential impacts of
the policies they advance. Further, punitive policies aimed primarily at
reducing drug company revenue—rather than those addressing specific market
failures or perverse incentives enshrined in existing law—will have negative
long-term impacts.
American
Action Forum (AAF) researchers have documented the potential impacts on
innovation of previous policies aimed at reducing pharmaceutical prices,
specifically the Trump Administration’s International Price Index (IPI)
proposal, and Speaker Pelosi’s H.R. 3.[7] These
proposals differ notably from the BBBA in that they tied price controls to the
price of a drug in designated foreign countries. As such, these analyses cannot
be directly applied to the BBBA, but they do provide some context for the
potential impact of this legislation’s price controls.
According
to AAF analysis of the aborted IPI proposal, if that demo had been applied to
all Part B drugs—expenditures for which equal roughly $30 billion—industry
revenues would have been reduced approximately $9 billion per year. Considering
that the cost of successfully bringing a drug to market has been estimated at
approximately $2.87 billion, the $9 billion in lost revenue per year
potentially attributable to the IPI proposal would be equivalent to the cost of
three new medicines each year, or 30 fewer new therapies over 10 years. In the
case of H.R. 3’s Average International Market (AIM) price, drug prices would be
capped at 120 percent of the index, rather than 126 percent in the IPI
proposal, and the capped price would be applied to all U.S. payers rather than
limited to Medicare Part B, which accounts for only 10 percent of all drug
expenditures in the United States.[8] If
the effect on drug development of the AIM price were similar to the impact of
the IPI, expanding those effects to 100 percent of the U.S. market would be the
equivalent of 30 fewer drugs per year or 60 percent of the total number of new
drugs approved by the Food and Drug Administration (FDA) in 2021.[9] Extrapolated
over 10 years, H.R. 3 would have potentially reduced industry revenue by the
equivalent cost of 300 new therapies. Of course, these proposals would be
unlikely to result in dollar-for-dollar reductions in R&D, so the actual
number of lost therapies would be lower. These estimates are also not directly
applicable to the BBBA because, whereas these past policies restrict drug
prices to a limited range based on established international prices, the BBBA
would implement a system of open-ended and steep price concessions based on
domestic prices and enforced by a staggering 95 percent tax on gross profits of
a particular therapy when a manufacturer fails to meet the Department of Health
and Human Services’ (HHS) price demands.
Philipson
and Durie, in a robust analysis of the BBBA provisions published November 2021,
estimate the legislation would reduce industry revenue by an astronomical $2.9
trillion through 2039. They attribute $1.77 trillion to the inflation rebates,
$986.9 billion to government “negotiation,” and $138.1 billion to the Part D
reforms. Using their estimates of the impact of revenue reductions on R&D
spending, the authors calculate that the BBBA would result in 135 fewer new
drug approvals by 2039, and that further disincentive to researching additional
indications will lead to 188 fewer new indications for existing therapies over
the same period. The authors also estimate that the policies would result in
331.5 million fewer life years through 2039. Significantly, the authors only
apply the inflation limits to Medicare, but the inflation penalties will limit
pricing in the private market as well, leading to even greater impacts on
future innovation. They also assume that prices will be set at the absolute highest
amount allowed under the BBBA, but there is no price floor, and the HHS
secretary would have substantial leverage to force price concessions well below
the maximum price.[10]
Rather
than being more limited in its impact on innovation than previous drug pricing
proposals, the BBBA’s deleterious effects would be at least comparable to past
proposals such as H.R. 3, and potentially even larger.
Medicare Negotiation for Drug Prices
Under
the BBBA, beginning in 2025, the HHS secretary would be authorized to
“negotiate” the prices of up to 10 “negotiation-eligible drugs.” In 2026 and
2027, the cap increases to 15 drugs annually, and rises to 20 drugs in 2028 and
beyond. Part B drugs—those drugs administered by a medical provider in a
hospital, nursing home, or similar setting—would be exempt until 2027.
Additionally, all insulin products would automatically be available for
negotiation beyond the yearly caps.
A
negotiation-eligible drug is defined as a small-molecule or biologic (including
authorized generics) treatment that has had FDA approval for at least seven
years for a small-molecule drug or 11 years for a biologic that is among the 50
single-source drugs with the highest total expenditures in Part B or Part D.
Orphan drugs or “low-spend” drugs are excluded, with low-spend being defined as
a drug or biologic on which Medicare spends less than $200 million annually
(adjusted by the consumer price index in future years). The reduced prices
would be effective after an additional two years, meaning small-molecule drugs
would have prices reduced nine years after approval and 13 years for biologics.
The
BBBA would set a ceiling for negotiated price of between 40-75 percent of the
non-federal average manufacturer price (AMP)—the average price paid by
wholesalers, net of prompt pay discounts—scaling down depending on how far the
drug is past its initial exclusivity period. There would, however, be no floor
below which HHS could not demand price concessions. Unlike H.R. 3, the
negotiated price would not be directly applied to the private health care
market, but the negotiated rate or “maximum fair price” would be publicized.
To
provide the HHS secretary with leverage in negotiations, the legislation would
establish an excise tax specifically on sales of drugs the secretary has
targeted for negotiation but for which the manufacturer has not agreed to the
secretary’s target price. The excise tax would be applied for any period in
which the manufacturer is in “non-compliance.” The tax would start out at 65
percent of sales of the therapy for the first 90 days of non-compliance,
increasing at regular intervals until topping out at 95 percent for any period
of non-compliance beyond 270 days.
The
claim that drug prices in Medicare Part D are not negotiated misstates the
reality of how Medicare pays for drugs. One might think from the rhetoric that
no negotiations occur between the Medicare prescription drug program and drug
manufacturers. In fact, the Medicare Part D program
has robust negotiation and competition built into its very fabric.[11] Insurance
companies offering drug coverage through Part D negotiate directly with
manufacturers to get the best price they can for the drugs they provide.
Getting a lower price benefits the prescription drug plan directly and allows
it to lower premiums to attract seniors. In this way, the negotiations drive
down premiums, copays, and overall drug costs. Plans are able to drive
discounts by offering preferred placement on their formularies to specific
therapies in exchange for lower prices. In some cases—with the exception of
specific protected classes of drugs—a plan might decline to cover a particular
therapy at all as part of its negotiations. This would be a problem if there
were only one formulary for all beneficiaries, but beneficiaries are able to
choose between a wide range of plan offerings, allowing them to select a plan
that best fits their needs. In 2022, the average Medicare beneficiary has
a choice of 23 stand-alone Part D plans, and 31 Medicare Advantage
plans that include drug coverage.[12]
To protect this competitive environment, federal
law prohibits the HHS secretary from interfering in the negotiations between
plans and manufacturers. The Congressional Budget Office (CBO) has long held that
simply removing this “noninterference” clause would not result in any savings
for the program because the secretary has no beneficiaries to negotiate on
behalf of, and no leverage for driving price concessions.[13] Giving the secretary the legal authority
to negotiate directly with manufacturers will either result in a single
negotiated price for each drug—which will then have to be accepted by all
insurers—thus undermining the competitive structure of Part D, or it will
result in nothing.
The
BBBA opts for the former, allowing the HHS secretary to set prices that will be
applied to all plans, and giving the secretary leverage to force price
concessions via the draconian 95 percent excise tax on gross profits for any
therapy whose manufacturer is unwilling to meet the secretary’s price demands.
Setting aside the negative long-term effects of the strict price controls
envisioned by the BBBA, proponents should dispense with the fiction that this
would resemble anything remotely like a negotiation. Given the 95 percent
excise tax the secretary would be free to wield against noncompliant
innovators, “price extortion” would be a more honest label for this provision
than “price negotiation.”
Inflation Penalties
The
BBBA would establish penalties for drugmakers if they increase the price of a
particular therapy faster than the rate of inflation. For drugs covered by Part
D, the AMP would be assumed as the base price of the drug for the purpose of
tracking price increases. A drug’s AMP would be benchmarked to October 2020,
while inflation would be benchmarked to September 2021. Drugmakers could still
increase their prices above inflation, but they would have to write a check for
the difference. For example, if a drug’s AMP was $110 per unit in October 2020,
and the inflation-adjusted AMP in 2023 is $120, but the actual AMP is $130, the
manufacturer would have to pay the government $10 for every unit sold in 2023.
The Part D inflation cap would apply to all drugs with a price of more than
$100 per patient, per year.
In
Part B, the principle is largely the same with a few differences. The price of
the drug to be considered would be the Average Sales Price (ASP). ASP would be
benchmarked to July 2021, while inflation would be benchmarked to September
2021. While both penalties would take effect in 2023, the Part B penalty would
be assessed quarterly, while the Part D penalty would be paid annually. The
penalty would be applied to all single-source drugs in Part B with costs
exceeding $100 per patient, per year—and biologics would still be considered
single source even if there were biosimilar competitors. Biosimilars would also
be subject to penalties if their price is above that of the reference product.
While
the BBBA would not apply Medicare’s negotiated prices for drugs to non-federal
programs, the most significant implication of the BBBA’s dollar-for-dollar
penalties on price increases that exceed the rate of inflation is that, for the
first time, the federal government would be unilaterally capping drug prices
nationwide, both in federal programs and in the private market. This shift in
the federal government’s posture toward private markets, negotiations, and
competition cannot be overstated.
Additionally,
the BBBA sets the inflation benchmark to a later date than the price benchmark.
As a result, the legislation extracts additional revenue from drugmakers to pay
for the BBBA’s other provisions—reinforcing the claim that at least part of the
purposes of the drug provisions is simply to generate money to pay for
unrelated new spending. If the policy benchmarked both drug price and inflation
to September 2021, CBO would likely have assumed that drugmakers would keep
their price increases to the rate of inflation. There would be savings due to
slower price growth over time, but they wouldn’t be huge. By capturing the
recent inflation spike and back-dating drug prices far enough to ensure that
pricing decisions already made are subject to the new policy, manufacturers
would have to pay for Democrats’ last year of inflationary spending policies.
Faced
with restrictions on future pricing flexibility, drugmakers would be
incentivized to increase initial launch prices in response to inflation penalties.
While these products would eventually be subject to HHS’s price-setting regime,
those forced price concessions would not take effect until years after the
product’s launch, further incentivizing manufacturers to maximize initial
profits through higher launch prices.
It
is worth noting that the BBBA drug provisions would be introduced in an
environment of general price inflation not seen in four decades. The imposition
of price controls on insulin and other drugs would guarantee that they will be underpriced
in real terms in very short order—a recipe for further inefficiency and damage
to innovation incentives. At the same time, there would be drugs that will see
their prices rise at inflation—because the BBBA essentially blesses such a
price rise as “legitimate”—even if no such increase is merited on the
fundamentals. The result would be prices that are too high in real terms and a
harm to consumers.
Insulin Price Restrictions
The
House-passed BBBA specifically targets insulin prices, making all insulin
products automatically subject to Medicare negotiation. The BBBA would also
unilaterally limit cost-sharing for insulin through Part D to $35 per month.
The
BBBA would further intercede in the group and individual insurance markets to
limit patient insulin costs. Starting in 2023, health insurers offering group
or individual health insurance coverage would be required to provide coverage
for at least one of each insulin dosage form (vial, pump, or inhaler) of each
type of insulin (rapid-acting, short-acting, intermediate-acting, long-acting,
and premixed). Further plans would be required to limit patient costs for
insulin to no more than either $35 for a 30-day supply, or an amount equal to
25 percent of the negotiated price of the insulin product for a 30-day
supply—net all price concessions—whichever is lower.
It
should also be noted that the BBBA’s heavy intervention in the insulin market,
popular though those provisions are likely to be, will risk curtailing
substantive innovation around insulin products and delivery mechanisms, as
there will be little financial incentive for companies to continue to invest in
their development.
Further,
recent data suggests such price controls may be unnecessary. The insulin market
has long suffered from the inability to sell “generic” insulins because of
complicated and outdated regulatory burdens; that issue was resolved in March
2020. In anticipation, manufacturers began developing new products and
accordingly, several authorized generics and a biosimilar have recently come to
market and compete with some of the most popular brand-name insulin products.
Following their introduction, the price per unit of insulin fell 6.8 percent
from 2018 to 2020, on average, across all insulin types, except
ultra-long-acting insulin.[14] This
is competition at work, lowering prices. There is, however, one caveat to this
point of success: Despite these new products having list prices of roughly half
that of their brand-name counterparts, use among patients thus far is
negligible—at least in Medicaid and Medicare Part D. It is likely that many
insurers are still providing preferential treatment on the formulary to the
brand-name products because such products typically come with substantial
rebates—reportedly averaging between 30-50 percent.[15] This
suggests rebate reform may be necessary to change this dynamic and allow the
public to actually reap the benefits of these lower cost products, as patients
pay coinsurance based on list price and the use of high-priced drugs increases
federal reinsurance spending.
Health Equity and Pharmaceutical Innovation
While the costs associated with innovative
therapies, particularly biologics, present access issues that can increase
disparities in health equity, policies like those included in the BBBA would
solve this problem, intentionally or not, by preventing new therapies from
being developed in the first place. Ironically, reduced innovation could
similarly impact health equity. According to Philipson and Durie, therapies
that treat diseases of the endocrine, cardiovascular, and respiratory systems
along with treatments for cancer and neurological diseases would be most
impacted by the BBBA’s policies because they make up a high share of Medicare
spending. Many conditions for which treatments are lacking in these categories
impact minority groups at higher rates. For example, 18.6 percent of African
Americans and 14 percent of Hispanics age 65 and older suffer from Alzheimer’s
compared to only 10 percent of Whites.[16] African Americans are also more likely die
of cancer or its complications than are Whites, 169.2 deaths per 100,000
compared to 150.3 deaths per 100,000.[17]
Given the recent focus
on insulin prices, it is significant that 14.5 percent of American Indians and
Alaska Natives, 12.1 percent of non-Hispanic African Americans, and 11.8
percent of Hispanics have diagnosed cases of diabetes compared to 9.5 percent
of Asian Americans and 7.4 percent of non-Hispanic Whites.[18] Similar trends
exist tied to educational attainment and family income. At the same time, 40.4
percent of non-Hispanic Whites with a diabetes diagnosis use insulin, compared
to 33.9 percent of non-Hispanic Blacks, and 31.1 percent of Hispanics.[19] In other words,
the impact of reduced innovation in insulin products will have a
disproportionate impact on racial minorities, yet those same groups are more
likely to struggle to access insulin therapies.
Clearly work is needed
to close the pharmaceutical access gap for disadvantaged groups, however,
policies that prevent new therapies from ever coming to market are a self-defeating
approach.
Impact
on Generic and Biosimilar Market Entry
Another
under-appreciated point of concern with the BBBA is the way the legislation’s
provisions could disincentivize future development of generic and biosimilar
therapies. Historically, flow-on products have led to significant cost savings
for American patients and have been a primary driver of prescription
medications’ relatively small share of total health care expenditures.
Ironically, the more successful the HHS secretary is in leveraging the BBBA’s
punitive excise tax to force price concessions, the fewer generic and
biosimilar products are likely to come to market. Follow-on products are able
to dramatically undercut name-brand drugs and biologics on price because they
do not have the same R&D expenditures and because their lower prices allow
them to achieve larger market shares. But if the price difference between a
name-brand drug, subject to the secretary’s price controls, and a new generic
is marginal or even non-existent, the ability of a generic to gain market share
will be reduced.
It may be that HHS is
able to drive sufficient price concessions—at the cost of future innovation—to
offset some of the lost savings due to a decimated generic and biosimilar
pipeline, but lower prices are not the only benefit of follow-on products.
Different patients respond differently to the same medication, so a robust
pipeline of follow-on therapies ensures patients are more likely to have access
to a therapy without unwanted side effects. Reduced market entry of generics
and biosimilars could lead to fewer options for doctors to help patients avoid
adverse reactions and side effects.
Economic
Damage to the Biopharmaceutical Sector
The biopharmaceutical
sector in the United States creates more than $1 trillion in economic activity
and employs more than 800,000 workers—at an average compensation over twice the
national average. More broadly, the industry supports more than 4 million jobs
across the U.S. economy, and generated over $67 billion in federal, state, and
local tax revenue in 2017 alone.
The BBBA’s policies
aimed at reducing industry revenues put this vibrant economic engine at risk.
In 1986, R&D investments by pharmaceutical firms in Europe exceeded R&D
in the United States by roughly 24 percent.[20] Following the
imposition of government price controls in many European countries, and
consequently the reduced return on investment, R&D spending by
pharmaceutical companies grew at an annual rate of just 5.4 percent in the
European Union, compared with 8.8 percent growth in the United States. As such,
more than half of the world’s pharmaceutical R&D investments have been made
in the United States since the turn of the century, whereas less than 30
percent has been invested in Europe.[21] While shifting
patterns of investment are the product of many factors, historically R&D
and manufacturing investments have moved away from countries in which strict
price control regimes are implemented. With countries such as India and China,
among others, aggressively seeking to bolster their own biopharmaceutical
industries, the BBBA would put at risk the economic benefits the United States
derives from the sector and would advantage other countries in their efforts to
lure away investments currently being made in this country.
Pharmaceutical
Policy Options to Consider
While many—though not
all—of the prescription drug pricing proposals included in the BBBA are unwise,
there are worthwhile solutions for tackling drug prices in ways that promote
competition and better align the incentives inherent in federal law.Medicare
Part D Reforms
On a positive note, the
House-passed BBBA does move in the right direction, undertaking a significant
redesign of the Medicare Part D program, beginning in 2024, aimed at realigning
plan and manufacturer incentives to constrain drug prices and to limit beneficiaries’
out-of-pocket (OOP) costs. A similar proposal was included in H.R. 19 by House
Republicans, and the broad framework of the proposal—originally outlined by AAF
in 2018—has garnered bipartisan support, although there have been partisan
differences over some of the details.[22]
Under the BBBA,
brand-name and biosimilar drug manufacturers would be liable for 10 percent of
costs in the initial coverage phase and 20 percent in the catastrophic phase.
Government reinsurance would fall to 20 percent for brand-name drugs and
biosimilars and to 40 percent for generic drugs. Insurer liability in the
catastrophic phase would increase to 60 percent for all drugs. The catastrophic
phase would begin at $2,000 in OOP costs, capping beneficiary costs at that
point. AAF originally considered capping beneficiary OOP costs between $2,500
and $4,000 annually. The BBBA OOP cap of $2,000 is significantly below what
beneficiaries are expected to pay before moving into the catastrophic phase
under current law. One potential improvement, recognizing budgetary constraints
and the need to balance savings for beneficiaries with costs for taxpayers,
would be a slightly higher OOP cap. This could be coupled with a reduction in
beneficiary coinsurance below the cap, which would benefit more enrollees—since
most will never reach the OOP cap—while still providing substantial savings for
taxpayers and enrollees who do reach the cap.
The BBBA would also reduce
beneficiaries’ coinsurance liability to 23 percent in the initial coverage
phase (from 25 percent currently) and their premium liability to 23.5 percent
(from 25.5 percent currently). Consequently, the federal premium subsidy rate
would rise to 76.5 percent (from 74.5 percent) and insurer liability in the
initial coverage phase would be 77 percent for generic drugs and 67 percent for
brand-names and biosimilars.
Last, the BBBA would
allow for beneficiaries’ OOP costs to be “smoothed” over the course of the
year, rather than potentially having to pay as much as $2,000 in a single
month.
While the BBBA version
of the Part D redesign retains the 10 percent manufacturer share in the initial
coverage phase that was added in the H.R. 3 version of the proposal, the
legislation would lower the manufacturer share in the catastrophic phase from
30 percent in H.R. 3 to 20 percent, while AAF initially proposed 9 percent
(note that AAF used 9 percent because that was determined to be the rate at
which pharmaceutical companies would be responsible for the same level of costs
at the time the original analysis was done, while AAF was neutral on whether
manufacturers’ share of costs should increase).
Drug
Rebate
In 2019, the Trump
Administration proposed significant changes to the structure of drug rebates.
While Congress has delayed and sought to repeal this rulemaking,[23] it would be wise
to reconsider. Under current law, drug manufacturers typically provide
significant rebates for drugs provided at the pharmacy counter (averaging
nearly 30 percent in Medicare Part D), especially for drugs with competing
alternatives. These rebates are most commonly paid to pharmacy benefit managers
(PBMs) in exchange for preferred placement on the insurance plan’s drug
formulary. The PBMs, however, do not usually share those rebates directly with
patients, instead typically using the rebates to hold down premium costs for
everyone. But using rebates on high-cost drugs to broadly lower premiums
instead of passing them through to beneficiaries results in the (high-cost)
sick subsidizing the (low-cost) healthy, which seems counter to the intent of
an insurance product.
The rebate rule, if
implemented, would change that practice. Drug rebates would no longer be
allowed unless they are completely passed through to the patient at the point
of sale. This change would almost certainly lead to increased Part D premiums,
which is why there has been opposition. Those increases are likely to be
minimal, however, as the cost increase would be spread across all
beneficiaries. On the other hand, the reduced cost-sharing expenses that the
highest-cost beneficiaries would see should outweigh those premium cost increases,
resulting in a net benefit to patients. Those patients with the highest costs
would see the greatest benefit. The Trump Administration could only propose
changes to affect rebates in the Medicare program through rulemaking; if
Congress were to enact a legislative version of the rebate rule, however, it
could extend the policy throughout the insurance system, which is an approach
worth consideration.
Competition
and Increased Supply
History has proven the
best way to reduce the price of a good for which there is growing demand is to
increase its supply through competition. For drug pricing, that means bringing
generics and biosimilars to market to compete with brand-name drugs.
A now-classic example of
this phenomenon is the Hepatitis C treatment, Sovaldi, which contributed over
$3 billion to 2014 expenditures alone.[24] While the drug was quite expensive, it is
important to note two things. First, Sovaldi—and its eventual
competitors—provided a cure for what had been up until that point a
costly-to-manage chronic disease. Second, as competitors joined the market, the
price of Sovaldi was cut in half. Where there is competition, prices come down.
The FDA has been doing its part by approving a record number of generic drugs
and biosimilars.[25] But other barriers to unlocking robust
market competition remain.
Legal Enforcement of Competition Policy
Often,
once a generic drug has been on the market long enough, it acquires enough of
the market share that the brand-name manufacturer stops producing its version
of the drug. In many cases, the price reaches a low enough point at which other
generic competitors also exit the market, leaving a sole manufacturer. In some
high-profile cases we see what amounts to abuse of monopoly power—that sole
manufacturer taking advantage of its position and dramatically increasing its
price once there is no more competition and consumers have no choice but to
purchase the now high-priced drug. In these cases, it should be treated as the
abuse that it is and prosecuted where appropriate.
Prosecuting
such monopoly abuses may require new authority for the Federal Trade Commission
(FTC). The FTC’s mission is “to prevent business practices that are
anticompetitive or deceptive or unfair to consumers.” The FTC notes that it has
limited authority to take action against a company that has drastically raised
the price of a drug, depending on the reason for the increase.
Drug Prices and the Challenge of Inflation
Some
policymakers have touted drug pricing reforms as a way to
address consumer price inflation. Inflation is a problem. As measured by the
Consumer Price Index (CPI) year-over-year inflation has risen from 1.4 percent
in January 2021 to 7.5 percent in January 2022. Reduced drug prices, however,
has essentially nothing to do with taming the economy-wide steady rise in
prices. Drug prices contribute only 1.4
percent of prices increases in the CPI, so changing drug prices
will little affect the overall total. Moreover, most of the proposals in BBBA
would not take full effect for years, and thus have no impact on inflation in
2022.
Conclusion
The
BBBA does not establish a true “negotiation” of drug prices in Medicare; rather
it would empower the HHS secretary to dictate prices to manufacturers who would
have little to no leverage. The BBBA would enshrine a unique and punitive 95
percent excise tax on gross profits of a therapy if the manufacturer does not
agree to the secretary’s demands and set a ceiling for a drug’s
price. Unlike past proposals, however, there is no floor price below
which the secretary would be unable to force further concessions. Significantly,
under the BBBA the federal government would cap the price of all drugs
throughout the entire health care system by penalizing any manufacturer who
increases a drug’s price faster than the rate of inflation.
The
combination of price setting by the HHS secretary and inflation penalties would
very likely reduce generic and biosimilar market entry, putting at risk
potential savings and improved treatment options for millions of Americans.
Price controls in the insulin market in particular will essentially eliminate
future improvements in insulins and may well be unnecessary as insulin prices
are beginning to drop with the emergence of greater competition. The BBBA’s
inflation penalties are also likely to result in higher launch prices and could
drive price increases commensurate with inflation for therapies whose prices
would not increase under current law.
Further,
the BBBA would reduce biopharmaceutical industry revenue by $2.9 trillion
through 2039 and puts at risk a U.S. biopharmaceutical sector that generates
more than $1 trillion in economic activity annually, employs more than 800,000
workers, and supports more than 4 million jobs across the U.S. economy. In the
mid-1980s, as European countries imposed stringent price controls, Europe saw a
flight of investment in drug development and manufacturing to the United
States. Under the BBBA, the United States would risk a similar loss in
competitiveness to countries such as India and China that are aggressively
seeking to bolster their own biopharmaceutical sectors.
The
BBBA would make large-scale changes to drug policy at the federal level and
reach deep into private insurance and contracts. These policies would have
widespread, negative impacts on the development of future therapies, new
indications for existing therapies, and the economic benefits the United States
derives from a vibrant biopharmaceutical sector. If the BBBA’s policies are
enacted in totality, American patients will suffer, American leadership in
medical research will be diminished, and a vibrant engine of economic
development for American workers and investors will be strangled. Congress
should discard the majority of the BBBA’s drug policies and instead focus on
pursuing bipartisan reforms to Medicare Part D and enacting changes to drug
rebates.
[1] https://www.healthaffairs.org/doi/10.1377/hlthaff.2021.01763
[2] https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical
[3] https://altarum.org/sites/default/files/uploaded-publication-files/Altarum%20Projections%20of%20the%20Non-Retail%20Dru.pdf
[4] https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf?_ga=2.112327436.987275036.1641911607-1139759599.1641911607
[5] https://www.americanactionforum.org/testimony/testimony-on-the-lower-drug-costs-now-act-h-r-3/
[6] https://cpb-us-w2.wpmucdn.com/voices.uchicago.edu/dist/d/3128/files/2021/08/Issue-Brief-Drug-Pricing-in-HR-5376-11.30.pdf
[7] https://www.americanactionforum.org/testimony/testimony-on-the-lower-drug-costs-now-act-h-r-3/
[8] https://www.americanactionforum.org/comments-for-record/comments-to-cms-on-proposed-international-pricing-index-for-medicare-part-b-drugs/
[9] https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021
[10] https://cpb-us-w2.wpmucdn.com/voices.uchicago.edu/dist/d/3128/files/2021/08/Issue-Brief-Drug-Pricing-in-HR-5376-11.30.pdf
[11] https://www.americanactionforum.org/research/competition-and-the-medicare-part-d-program/
[12] https://www.kff.org/medicare/issue-brief/medicare-part-d-a-first-look-at-medicare-prescription-drug-plans-in-2022/
[13] https://www.cbo.gov/sites/default/files/108th-congress-2003-2004/reports/fristletter.pdf
[14] https://www.americanactionforum.org/insight/insulin-prices-an-update/
[15] https://www.americanactionforum.org/research/insulin-cost-and-pricing-trends/
[16] https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf
[17] https://gis.cdc.gov/Cancer/USCS/#/Demographics/
[18] https://www.cdc.gov/diabetes/data/statistics-report/appendix.html#tabs-1-3
[19] https://gis.cdc.gov/grasp/diabetes/DiabetesAtlas.html#
[20] https://www.nber.org/papers/w12676
[21] https://www.abpi.org.uk/facts-and-figures/science-and-innovation/worldwide-pharmaceutical-company-rd-expenditure-by-country/
[22] https://www.americanactionforum.org/research/redesigning-medicare-part-d-realign-incentives-1/
[23] https://www.americanactionforum.org/weekly-checkup/a-dramatic-attempt-to-lower-drug-costs/
[24] https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/index.html
[25] https://www.fda.gov/NewsEvents/Newsroom/FDAInBrief/ucm625627.htm
https://www.americanactionforum.org/testimony/testimony-on-the-build-back-better-acts-prescription-drug-policies-and-their-potential-impacts/#ixzz7ONAh0qTd
Follow @AAF on Twitter
No comments:
Post a Comment